286 related articles for article (PubMed ID: 36342475)
1. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Kang J; Park KW; Lee H; Hwang D; Yang HM; Rha SW; Bae JW; Lee NH; Hur SH; Han JK; Shin ES; Koo BK; Kim HS
Circulation; 2023 Jan; 147(2):108-117. PubMed ID: 36342475
[TBL] [Abstract][Full Text] [Related]
2. Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Shin ES; Jun EJ; Kim B; Won KB; Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Han JK; Kim HS;
J Am Heart Assoc; 2023 Apr; 12(8):e026770. PubMed ID: 37042284
[TBL] [Abstract][Full Text] [Related]
3. Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A Post Hoc Analysis From the HOST-EXAM Extended Study.
Lee K; Kang J; Park KW; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Yang HM; Kang HJ; Han JK; Shin ES; Koo BK; Kim HS
Can J Cardiol; 2024 Jan; 40(1):43-52. PubMed ID: 37742741
[TBL] [Abstract][Full Text] [Related]
4. Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
Rhee TM; Bae JW; Park KW; Rha SW; Kang J; Lee H; Yang HM; Kwak SH; Chae IH; Shin WY; Kim DK; Oh JH; Jeong MH; Kim YH; Lee NH; Hur SH; Yoon J; Han JK; Shin ES; Koo BK; Kim HS;
JAMA Cardiol; 2023 Jun; 8(6):535-544. PubMed ID: 37043192
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Yang S; Kang J; Park KW; Hur SH; Lee NH; Hwang D; Yang HM; Ahn HS; Cha KS; Jo SH; Ryu JK; Suh IW; Choi HH; Woo SI; Han JK; Shin ES; Koo BK; Kim HS
J Am Coll Cardiol; 2023 Oct; 82(16):1565-1578. PubMed ID: 37821166
[TBL] [Abstract][Full Text] [Related]
6. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Wu H; Xu L; Zhao X; Zhang H; Cheng K; Wang X; Chen M; Li G; Huang J; Lan J; Wei G; Zhang C; Wang Y; Qian J; Ge J;
Circulation; 2023 Jan; 147(3):212-222. PubMed ID: 36335890
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
[TBL] [Abstract][Full Text] [Related]
8. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Koo BK; Kang J; Park KW; Rhee TM; Yang HM; Won KB; Rha SW; Bae JW; Lee NH; Hur SH; Yoon J; Park TH; Kim BS; Lim SW; Cho YH; Jeon DW; Kim SH; Han JK; Shin ES; Kim HS;
Lancet; 2021 Jun; 397(10293):2487-2496. PubMed ID: 34010616
[TBL] [Abstract][Full Text] [Related]
9. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
[TBL] [Abstract][Full Text] [Related]
10. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.
Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y;
JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489
[TBL] [Abstract][Full Text] [Related]
11. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Obayashi Y; Watanabe H; Morimoto T; Yamamoto K; Natsuaki M; Domei T; Yamaji K; Suwa S; Isawa T; Watanabe H; Yoshida R; Sakamoto H; Akao M; Hata Y; Morishima I; Tokuyama H; Yagi M; Suzuki H; Wakabayashi K; Suematsu N; Inada T; Tamura T; Okayama H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
Circ Cardiovasc Interv; 2022 Aug; 15(8):e012004. PubMed ID: 35912647
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821
[TBL] [Abstract][Full Text] [Related]
13. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
14. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
[TBL] [Abstract][Full Text] [Related]
15. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
[TBL] [Abstract][Full Text] [Related]
18. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
19. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
